No CrossRef data available.
Article contents
Clozapine in the Treatement of Refractory Bipolar Disorder
Published online by Cambridge University Press: 15 April 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Clozapine is a second-generation antipsychotic, it. has been used in bipolar disorder refractory since 1989. Its use has been shown to reduce symptom severity in patients with manic and mixed-state episodes. The aim of this paper is to systematically review data published in 2014 to evaluate the effectiveness of clozapine in BD
Methods
the Medline database was searched for 2014 publications using the following keywords: ‘clozapine’; ‘refractory bipolar disorder’; ‘ effectiveness’; ‘ side effects’.
Results
Medline search returned 110 results. Manual inspection of abstracts allowed selecting six papers for further review.
The first meta-analysis of the efficacy of clozapine in the treatement of refractory bipolar disorder, published in2014,showed the effectiveness and safety of rapid clozapine titration by decreasing the need for psychotropic co-medications, and reducing the number of psychiatric hospitalization. Other papers suggested that this molecule present adverse reaction associated with problems in clinical and biological tolerance which explains its abondan.
Conclusion
clozapine used at low dose is a molecule of future in the treatment of bipolar disorder and recent publication showed that its side effects join the other second generation antipsychotics
- Type
- Article: 0454
- Information
- European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
- Copyright
- Copyright © European Psychiatric Association 2015
You have
Access
Comments
No Comments have been published for this article.